The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection

Current Medicinal Chemistry

Volumn 18, Issue 4, 2011, Pages 497-512

  Patrussi, L ^a   Baldari, C T ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Agonist; Analogue; Antagonist; Cancer; CXCL12; CXCR4; Hematopoietic progenitor mobilization; HIV 1

Indexed keywords

17 MER TACHYPLESIN; 18 MER POLYPHEMUSIN; 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; BKT 140; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTIBODY; CTCE 0021; CTCE 0214; CTCE 9908; FC 131; KRH 1636; KRH 3955; N 33A; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PLERIXAFOR; POL 3026; RCP 168; RCP 222; STROMAL CELL DERIVED FACTOR 1; T 140; T 22; TC 14012; TN 14003; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC 2,2 DIPICOLYLAMINE; ZINC DIPICOLYLAMINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; BILE DUCT CARCINOMA; BREAST CANCER; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME INHIBITION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOPHYSIS ADENOMA; IC 50; LIMULUS; LIMULUS POLYPHEMUS; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN FUNCTION; REPEATED DRUG DOSE; RHABDOMYOSARCOMA; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; STOMACH CANCER; TACHYPLEUS TRIDENTATUS; THYROID CARCINOMA; VIRUS INHIBITION;

ANTINEOPLASTIC AGENTS; CHEMOKINE CXCL12; HIV INFECTIONS; HIV-1; HUMANS; NEOPLASMS; PEPTIDES; RECEPTORS, CXCR4; SMALL MOLECULE LIBRARIES;

EID: 79851477828     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794480159     Document Type: Article

References (156)

1. Horuk, R. Chemokine receptors. Cytokine Growth Factor Rev., 2001, 12, 313-335. (Pubitemid 32851745)
2. Loetscher, M.; Geiser, T.; O'Reilly, T.; Zwahlen, R.; Baggiolini, M.; Moser, B. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J. Biol. Chem., 1994, 269, 232-235.
3. Alkhatib, G. The biology of CCR5 and CXCR4. Curr. Opin. HIV AIDS, 2009, 4, 96-103.
4. Marchese, A.; Paing, M. M.; Temple, B. R.; Trejo, J. G proteincoupled receptor sorting to endosomes and lysosomes. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 601-604.
5. Murphy, P. M. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol., 1994, 12, 593-633. (Pubitemid 24140426)
6. Bommakanti, R. K.; Dratz, E. A.; Siemsen, D. W.; Jesaitis, A. J. Extensive contact between Gi2 and N-formyl peptide receptor of human neutrophils: mapping of binding sites using receptormimetic peptides. Biochemistry, 1995, 34, 6720-6728.
7. Oberlin, E.; Amara, A.; Bachelerie, F.; Bessia, C.; Virelizier, J. L.; Arenzana-Seisdedos, F.; Schwartz, O.; Heard, J. M.; Clark-Lewis, I.; Legler, D. F.; Loetscher, M.; Baggiolini, M.; Moser, B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature, 1996, 382, 833-835. (Pubitemid 26299571)
8. Bleul, C. C.; Fuhlbrigge, R. C.; Casasnovas, J. M.; Aiuti, A.; Springer, T. A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med., 1996, 184, 1101-1109. (Pubitemid 26313567)
9. Veldkamp, C. T.; Ziarek, J. J.; Su, J.; Basnet, H.; Lennertz, R.; Weiner, J. J.; Peterson, F. C.; Baker, J. E.; Volkman, B. F. Monomeric structure of the cardioprotective chemokine SDF-1/CXCL12. Protein Sci., 2009, 18, 1359-1362.
10. Kofuku, Y.; Yoshiura, C.; Ueda, T.; Terasawa, H.; Hirai, T.; Tominaga, S.; Hirose, M.; Maeda, Y.; Takahashi, H.; Terashima, Y.; Matsushima, K.; Shimada, I. Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4. J. Biol. Chem., 2009, 284, 35240-35250.
11. Ma, Q.; Jones, D.; Borghesani, P. R.; Segal, R. A.; Nagasawa, T.; Kishimoto, T.; Bronson, R. T.; Springer, T. A. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc. Natl. Acad. Sci. USA, 1998, 95, 9448-9453. (Pubitemid 28506251)
12. Nagasawa, T.; Hirota, S.; Tachibana, K.; Takakura, N.; Nishikawa, S.; Kitamura, Y.; Yoshida, N.; Kikutani, H.; Kishimoto, T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature, 1996, 382, 635-638. (Pubitemid 26268957)
13. Burns, J. M.; Summers, B. C.; Wang, Y.; Melikian, A.; Berahovich, R.; Miao, Z.; Penfold, M. E.; Sunshine, M. J.; Littman, D. R.; Kuo, C. J.; Wei, K.; McMaster, B. E.; Wright, K.; Howard, M. C.; Schall, T. J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med., 2006, 203, 2201-2205.
14. Thelen, M.; Thelen, S. CXCR7, CXCR4 and CXCL12: an eccentric trio? J Neuroimmunol., 2008, 198, 9-14.
15. Doranz, B. J.; Berson, J. F.; Rucker, J.; Doms, R. W. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Immunol. Res., 1997, 16, 15-28. (Pubitemid 27129627)
16. Bleul, C. C.; Farzan, M.; Choe, H.; Parolin, C.; Clark-Lewis, I.; Sodroski, J.; Springer, T. A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature, 1996, 382, 829-833. (Pubitemid 26299570)
17. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 1996, 272, 872-877. (Pubitemid 26154590)
18. Wu, X.; Lee, V. C.; Chevalier, E.; Hwang, S. T. Chemokine receptors as targets for cancer therapy. Curr. Pharm. Des., 2009, 15, 742-757.
19. Hinton, C. V.; Avraham, S.; Avraham, H. K. Role of the CXCL12/CXCR4 signaling axis in breast cancer metastasis to the brain. Clin. Exp. Metastasis, 2010, 27, 97-105.
20. Ooi, L. L.; Dunstan, C. R. CXCL12/CXCR4 axis in tissue targeting and bone destruction in cancer and multiple myeloma. J. Bone Miner. Res., 2009, 24, 1147-1149.
21. Mongan, J. P.; Fadul, C. E.; Cole, B. F.; Zaki, B. I.; Suriawinata, A. A.; Ripple, G. H.; Tosteson, T. D.; Pipas, J. M. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin. Colorectal Cancer, 2009, 8, 100-105.
22. Otsuka, S.; Bebb, G. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer. J. Thorac. Oncol., 2008, 3, 1379-1383.
23. Orimo, A.; Gupta, P. B.; Sgroi, D. C.; Arenzana-Seisdedos, F.; Delaunay, T.; Naeem, R.; Carey, V. J.; Richardson, A. L.; Weinberg, R. A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 2005, 121, 335-348. (Pubitemid 40692295)
24. Orimo, A.; Weinberg, R. A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle, 2006, 5, 1597-1601. (Pubitemid 44285243)
25. Liotta, L. A. An attractive force in metastasis. Nature, 2001, 410, 24-25. (Pubitemid 32225818)
26. Nanki, T.; Hayashida, K.; El-Gabalawy, H. S.; Suson, S.; Shi, K.; Girschick, H. J.; Yavuz, S.; Lipsky, P. E. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J. Immunol., 2000, 165, 6590-6598.
27. Strieter, R. M.; Keeley, E. C.; Burdick, M. D.; Mehrad, B. The role of circulating mesenchymal progenitor cells, fibrocytes, in promoting pulmonary fibrosis. Trans. Am. Clin. Climatol. Assoc., 2009, 120, 49-59.
28. Andersson-Sjoland, A.; de Alba, C. G.; Nihlberg, K.; Becerril, C.; Ramirez, R.; Pardo, A.; Westergren-Thorsson, G.; Selman, M. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol., 2008, 40, 2129-2140.
29. Schols, D.; Struyf, S.; Van Damme, J.; Este, J. A.; Henson, G.; De Clercq, E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med., 1997, 186, 1383-1388. (Pubitemid 27469034)
30. Murakami, T.; Nakajima, T.; Koyanagi, Y.; Tachibana, K.; Fujii, N.; Tamamura, H.; Yoshida, N.; Waki, M.; Matsumoto, A.; Yoshie, O.; Kishimoto, T.; Yamamoto, N.; Nagasawa, T. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med., 1997, 186, 1389-1393. (Pubitemid 27469035)
31. Tsutsumi, H.; Tanaka, T.; Ohashi, N.; Masuno, H.; Tamamura, H.; Hiramatsu, K.; Araki, T.; Ueda, S.; Oishi, S.; Fujii, N. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers, 2007, 88, 279-289. (Pubitemid 46661507)
32. Miyata, T.; Tokunaga, F.; Yoneya, T.; Yoshikawa, K.; Iwanaga, S.; Niwa, M.; Takao, T.; Shimonishi, Y. Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity. J. Biochem., 1989, 106, 663-668.
33. Nakamura, T.; Furunaka, H.; Miyata, T.; Tokunaga, F.; Muta, T.; Iwanaga, S.; Niwa, M.; Takao, T.; Shimonishi, Y. Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus). Isolation and chemical structure. J. Biol. Chem., 1988, 263, 16709-16713. (Pubitemid 18268849)
34. Masuda, M.; Nakashima, H.; Ueda, T.; Naba, H.; Ikoma, R.; Otaka, A.; Terakawa, Y.; Tamamura, H.; Ibuka, T.; Murakami, T. A novel anti-HIV synthetic peptide, T-22 ([Tyr5, 12, Lys7]-polyphemusin II). Biochem. Biophys. Res. Commun., 1992, 189, 845-850. (Pubitemid 23032451)
35. Nakashima, H.; Masuda, M.; Murakami, T.; Koyanagi, Y.; Matsumoto, A.; Fujii, N.; Yamamoto, N. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5, 12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother., 1992, 36, 1249-1255.
36. Murakami, T.; Zhang, T. Y.; Koyanagi, Y.; Tanaka, Y.; Kim, J.; Suzuki, Y.; Minoguchi, S.; Tamamura, H.; Waki, M.; Matsumoto, A.; Fujii, N.; Shida, H.; Hoxie, J. A.; Peiper, S. C.; Yamamoto, N. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J. Virol., 1999, 73, 7489-7496. (Pubitemid 29383232)
37. Arakaki, R.; Tamamura, H.; Premanathan, M.; Kanbara, K.; Ramanan, S.; Mochizuki, K.; Baba, M.; Fujii, N.; Nakashima, H. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J. Virol., 1999, 73, 1719-1723. (Pubitemid 29036837)
38. Xu, Y.; Tamamura, H.; Arakaki, R.; Nakashima, H.; Zhang, X.; Fujii, N.; Uchiyama, T.; Hattori, T. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. AIDS Res. Hum. Retroviruses, 1999, 15, 419-427. (Pubitemid 29143199)
39. Tamamura, H.; Imai, M.; Ishihara, T.; Masuda, M.; Funakoshi, H.; Oyake, H.; Murakami, T.; Arakaki, R.; Nakashima, H.; Otaka, A.; Ibuka, T.; Waki, M.; Matsumoto, A.; Yamamoto, N.; Fujii, N. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr (5, 12), Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Bioorg. Med. Chem., 1998, 6, 1033-1041. (Pubitemid 28464534)
40. Boulais, P. E.; Dulude, D.; Cabana, J.; Heveker, N.; Escher, E.; Lavigne, P.; Leduc, R. Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site. Biochem. Pharmacol., 2009, 78, 1382-1390.
41. Zhang, W. B.; Navenot, J. M.; Haribabu, B.; Tamamura, H.; Hiramatu, K.; Omagari, A.; Pei, G.; Manfredi, J. P.; Fujii, N.; Broach, J. R.; Peiper, S. C. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J. Biol. Chem., 2002, 277, 24515-24521. (Pubitemid 34951977)
42. Tamamura, H.; Omagari, A.; Oishi, S.; Kanamoto, T.; Yamamoto, N.; Peiper, S. C.; Nakashima, H.; Otaka, A.; Fujii, N. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg. Med. Chem. Lett., 2000, 10, 2633-2637.
43. Tamamura, H.; Omagari, A.; Hiramatsu, K.; Gotoh, K.; Kanamoto, T.; Xu, Y.; Kodama, E.; Matsuoka, M.; Hattori, T.; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg. Med. Chem. Lett., 2001, 11, 1897-1902. (Pubitemid 32675313)
44. Tamamura, H.; Fujisawa, M.; Hiramatsu, K.; Mizumoto, M.; Nakashima, H.; Yamamoto, N.; Otaka, A.; Fujii, N. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett., 2004, 569, 99-104. (Pubitemid 38844600)
45. Burger, J. A.; Peled, A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia, 2009, 23, 43-52.
46. Tamamura, H.; Fujii, N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin. Ther. Targets, 2005, 9, 1267-1282. (Pubitemid 41781486)
47. Takenaga, M.; Tamamura, H.; Hiramatsu, K.; Nakamura, N.; Yamaguchi, Y.; Kitagawa, A.; Kawai, S.; Nakashima, H.; Fujii, N.; Igarashi, R. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem. Biophys. Res. Commun., 2004, 320, 226-232. (Pubitemid 38781805)
48. Burger, M.; Glodek, A.; Hartmann, T.; Schmitt-Graff, A.; Silberstein, L. E.; Fujii, N.; Kipps, T. J.; Burger, J. A. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene, 2003, 22, 8093-8101. (Pubitemid 37487300)
49. Burger, J. A.; Stewart, D. J. CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin. Investig. Drugs, 2009, 18, 481-490.
50. Mori, T.; Doi, R.; Koizumi, M.; Toyoda, E.; Ito, D.; Kami, K.; Masui, T.; Fujimoto, K.; Tamamura, H.; Hiramatsu, K.; Fujii, N.; Imamura, M. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol. Cancer Ther., 2004, 3, 29-37. (Pubitemid 39193676)
51. Juarez, J.; Baraz, R.; Gaundar, S.; Bradstock, K.; Bendall, L. Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia. Haematologica, 2007, 92, 450-459. (Pubitemid 350144290)
52. Burger, M.; Hartmann, T.; Krome, M.; Rawluk, J.; Tamamura, H.; Fujii, N.; Kipps, T. J.; Burger, J. A. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood, 2005, 106, 1824-1830. (Pubitemid 41208600)
53. Martin, S. K.; Dewar, A. L.; Farrugia, A. N.; Horvath, N.; Gronthos, S.; To, L. B.; Zannettino, A. C. Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma. Clin. Cancer Res., 2006, 12, 6973-6877.
54. Zannettino, A. C.; Farrugia, A. N.; Kortesidis, A.; Manavis, J.; To, L. B.; Martin, S. K.; Diamond, P.; Tamamura, H.; Lapidot, T.; Fujii, N.; Gronthos, S. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res., 2005, 65, 1700-1709. (Pubitemid 40478595)
55. Libura, J.; Drukala, J.; Majka, M.; Tomescu, O.; Navenot, J. M.; Kucia, M.; Marquez, L.; Peiper, S. C.; Barr, F. G.; Janowska-Wieczorek, A.; Ratajczak, M. Z. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood, 2002, 100, 2597-2606.
56. Hart, C. A.; Brown, M.; Bagley, S.; Sharrard, M.; Clarke, N. W. Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br. J. Cancer, 2005, 92, 503-512. (Pubitemid 40395531)
57. Abraham, M.; Beider, K.; Wald, H.; Weiss, I. D.; Zipori, D.; Galun, E.; Nagler, A.; Eizenberg, O.; Peled, A. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia, 2009, 23, 1378-1388.
58. Petit, I.; Szyper-Kravitz, M.; Nagler, A.; Lahav, M.; Peled, A.; Habler, L.; Ponomaryov, T.; Taichman, R. S.; Arenzana-Seisdedos, F.; Fujii, N.; Sandbank, J.; Zipori, D.; Lapidot, T. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and upregulating CXCR4. Nat. Immunol., 2002, 3, 687-694. (Pubitemid 34752479)
59. Fujii, N.; Oishi, S.; Hiramatsu, K.; Araki, T.; Ueda, S.; Tamamura, H.; Otaka, A.; Kusano, S.; Terakubo, S.; Nakashima, H.; Broach, J. A.; Trent, J. O.; Wang, Z. X.; Peiper, S. C. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation-and sequence-based libraries. Angew Chem. Int. Ed. Engl., 2003, 42, 3251-3253. (Pubitemid 36917168)
60. Vabeno, J.; Nikiforovich, G. V.; Marshall, G. R. A minimalistic 3D pharmacophore model for cyclopentapeptide CXCR4 antagonists. Biopolymers, 2006, 84, 459-471. (Pubitemid 44523320)
61. Tamamura, H.; Hiramatsu, K.; Ueda, S.; Wang, Z.; Kusano, S.; Terakubo, S.; Trent, J. O.; Peiper, S. C.; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl) alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J. Med. Chem., 2005, 48, 380-391.
62. Tamamura, H.; Esaka, A.; Ogawa, T.; Araki, T.; Ueda, S.; Wang, Z.; Trent, J. O.; Tsutsumi, H.; Masuno, H.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Otaka, A.; Fujii, N. Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. Org. Biomol. Chem., 2005, 3, 4392-4394. (Pubitemid 43035623)
63. Tamamura, H.; Araki, T.; Ueda, S.; Wang, Z.; Oishi, S.; Esaka, A.; Trent, J. O.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Otaka, A.; Fujii, N. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J. Med. Chem., 2005, 48, 3280-3289. (Pubitemid 40628048)
64. Tamamura, H.; Tsutsumi, H.; Masuno, H.; Mizokami, S.; Hiramatsu, K.; Wang, Z.; Trent, J. O.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Fujii, N. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs. Org. Biomol. Chem., 2006, 4, 2354-2357. (Pubitemid 43882756)
65. Tamamura, H.; Tsutsumi, H.; Masuno, H.; Fujii, N. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra-and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Curr. Med. Chem., 2007, 14, 93-102. (Pubitemid 46050306)
66. Doranz, B. J.; Grovit-Ferbas, K.; Sharron, M. P.; Mao, S. H.; Goetz, M. B.; Daar, E. S.; Doms, R. W.; O'Brien, W. A. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med., 1997, 186, 1395-1400. (Pubitemid 27469036)
67. Doranz, B. J.; Filion, L. G.; Diaz-Mitoma, F.; Sitar, D. S.; Sahai, J.; Baribaud, F.; Orsini, M. J.; Benovic, J. L.; Cameron, W.; Doms, R. W. Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res. Hum. Retroviruses, 2001, 17, 475-486. (Pubitemid 32692330)
68. DeMarco, S. J.; Henze, H.; Lederer, A.; Moehle, K.; Mukherjee, R.; Romagnoli, B.; Robinson, J. A.; Brianza, F.; Gombert, F. O.; Lociuro, S.; Ludin, C.; Vrijbloed, J. W.; Zumbrunn, J.; Obrecht, J. P.; Obrecht, D.; Brondani, V.; Hamy, F.; Klimkait, T. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorg. Med. Chem., 2006, 14, 8396-8404. (Pubitemid 44667545)
69. Moncunill, G.; Armand-Ugon, M.; Clotet-Codina, I.; Pauls, E.; Ballana, E.; Llano, A.; Romagnoli, B.; Vrijbloed, J. W.; Gombert, F. O.; Clotet, B.; De Marco, S.; Este, J. A. Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026. Mol. Pharmacol., 2008, 73, 1264-1273. (Pubitemid 351439208)
70. De Clercq, E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem. Pharmacol., 2009, 77, 1655-1664.
71. Donzella, G. A.; Schols, D.; Lin, S. W.; Este, J. A.; Nagashima, K. A.; Maddon, P. J.; Allaway, G. P.; Sakmar, T. P.; Henson, G.; De Clercq, E.; Moore, J. P. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med., 1998, 4, 72-77. (Pubitemid 28133082)
72. De Vreese, K.; Van Nerum, I.; Vermeire, K.; Anne, J.; De Clercq, E. Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120. Antimicrob. Agents Chemother., 1997, 41, 2616-2620. (Pubitemid 27524730)
73. Fricker, S. P.; Anastassov, V.; Cox, J.; Darkes, M. C.; Grujic, O.; Idzan, S. R.; Labrecque, J.; Lau, G.; Mosi, R. M.; Nelson, K. L.; Qin, L.; Santucci, Z.; Wong, R. S. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem. Pharmacol., 2006, 72, 588-596. (Pubitemid 44163295)
74. De Clercq, E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol. Pharmacol., 2000, 57, 833-839. (Pubitemid 30253364)
75. Hatse, S.; Princen, K.; Gerlach, L. O.; Bridger, G.; Henson, G.; De Clercq, E.; Schwartz, T. W.; Schols, D. Mutation of Asp (171) and Asp (262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol. Pharmacol., 2001, 60, 164-173. (Pubitemid 32595244)
76. Hendrix, C. W.; Flexner, C.; MacFarland, R. T.; Giandomenico, C.; Fuchs, E. J.; Redpath, E.; Bridger, G.; Henson, G. W. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother., 2000, 44, 1667-1673. (Pubitemid 30340812)
77. Hendrix, C. W.; Collier, A. C.; Lederman, M. M.; Schols, D.; Pollard, R. B.; Brown, S.; Jackson, J. B.; Coombs, R. W.; Glesby, M. J.; Flexner, C. W.; Bridger, G. J.; Badel, K.; MacFarland, R. T.; Henson, G. W.; Calandra, G. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr., 2004, 37, 1253-1262. (Pubitemid 39281506)
78. Broxmeyer, H. E.; Orschell, C. M.; Clapp, D. W.; Hangoc, G.; Cooper, S.; Plett, P. A.; Liles, W. C.; Li, X.; Graham-Evans, B.; Campbell, T. B.; Calandra, G.; Bridger, G.; Dale, D. C.; Srour, E. F. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med., 2005, 201, 1307-1318. (Pubitemid 40629073)
79. Liles, W. C.; Rodger, E.; Broxmeyer, H. E.; Dehner, C.; Badel, K.; Calandra, G.; Christensen, J.; Wood, B.; Price, T. H.; Dale, D. C. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocytecolony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion, 2005, 45, 295-300. (Pubitemid 40389423)
80. Flomenberg, N.; Devine, S. M.; Dipersio, J. F.; Liesveld, J. L.; McCarty, J. M.; Rowley, S. D.; Vesole, D. H.; Badel, K.; Calandra, G. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood, 2005, 106, 1867-1874. (Pubitemid 41208607)
81. Cashen, A. F. Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. Drugs Today (Barc), 2009, 45, 497-505.
82. Alsayed, Y.; Ngo, H.; Runnels, J.; Leleu, X.; Singha, U. K.; Pitsillides, C. M.; Spencer, J. A.; Kimlinger, T.; Ghobrial, J. M.; Jia, X.; Lu, G.; Timm, M.; Kumar, A.; Cote, D.; Veilleux, I.; Hedin, K. E.; Roodman, G. D.; Witzig, T. E.; Kung, A. L.; Hideshima, T.; Anderson, K. C.; Lin, C. P.; Ghobrial, I. M. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood, 2007, 109, 2708-2717. (Pubitemid 46482062)
83. Wagstaff, A. J. Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma. Drugs, 2009, 69, 319-326.
84. Devine, S. M.; Flomenberg, N.; Vesole, D. H.; Liesveld, J.; Weisdorf, D.; Badel, K.; Calandra, G.; DiPersio, J. F. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol., 2004, 22, 1095-1102. (Pubitemid 41095043)
85. Gazitt, Y.; Freytes, C. O.; Akay, C.; Badel, K.; Calandra, G. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev., 2007, 16, 657-666. (Pubitemid 47378738)
86. Matthys, P.; Hatse, S.; Vermeire, K.; Wuyts, A.; Bridger, G.; Henson, G. W.; De Clercq, E.; Billiau, A.; Schols, D. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J. Immunol., 2001, 167, 4686-4692. (Pubitemid 32954350)
87. Rubin, J. B.; Kung, A. L.; Klein, R. S.; Chan, J. A.; Sun, Y.; Schmidt, K.; Kieran, M. W.; Luster, A. D.; Segal, R. A. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl. Acad. Sci. USA, 2003, 100, 13513-13518. (Pubitemid 37444773)
88. Kioi, M.; Vogel, H.; Schultz, G.; Hoffman, R. M.; Harsh, G. R.; Brown, J. M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest., 2010, 120, 694-705.
89. Ngo, H. T.; Leleu, X.; Lee, J.; Jia, X.; Melhem, M.; Runnels, J.; Moreau, A. S.; Burwick, N.; Azab, A. K.; Roccaro, A.; Azab, F.; Sacco, A.; Farag, M.; Sackstein, R.; Ghobrial, I. M. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood, 2008, 112, 150-158.
90. Cabioglu, N.; Sahin, A.; Doucet, M.; Yavuz, E.; Igci, A.; E, O. Y.; Aktas, E.; Bilgic, S.; Kiran, B.; Deniz, G.; Price, J. E. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin. Exp. Metastasis, 2005, 22, 39-46. (Pubitemid 41185860)
91. Smith, M. C.; Luker, K. E.; Garbow, J. R.; Prior, J. L.; Jackson, E.; Piwnica-Worms, D.; Luker, G. D. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res., 2004, 64, 8604-8612. (Pubitemid 39552073)
92. Marchesi, F.; Monti, P.; Leone, B. E.; Zerbi, A.; Vecchi, A.; Piemonti, L.; Mantovani, A.; Allavena, P. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res., 2004, 64, 8420-8427. (Pubitemid 39491782)
93. Ohira, S.; Sasaki, M.; Harada, K.; Sato, Y.; Zen, Y.; Isse, K.; Kozaka, K.; Ishikawa, A.; Oda, K.; Nimura, Y.; Nakanuma, Y. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am. J. Pathol., 2006, 168, 1155-1168.
94. Scala, S.; Giuliano, P.; Ascierto, P. A.; Ierano, C.; Franco, R.; Napolitano, M.; Ottaiano, A.; Lombardi, M. L.; Luongo, M.; Simeone, E.; Castiglia, D.; Mauro, F.; De Michele, I.; Calemma, R.; Botti, G.; Caraco, C.; Nicoletti, G.; Satriano, R. A.; Castello, G. Human melanoma metastases express functional CXCR4. Clin. Cancer Res., 2006, 12, 2427-2433.
95. Scotton, C. J.; Wilson, J. L.; Scott, K.; Stamp, G.; Wilbanks, G. D.; Fricker, S.; Bridger, G.; Balkwill, F. R. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res., 2002, 62, 5930-5938. (Pubitemid 35204756)
96. Yasumoto, K.; Koizumi, K.; Kawashima, A.; Saitoh, Y.; Arita, Y.; Shinohara, K.; Minami, T.; Nakayama, T.; Sakurai, H.; Takahashi, Y.; Yoshie, O.; Saiki, I. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res., 2006, 66, 2181-2187.
97. Juarez, J.; Bradstock, K. F.; Gottlieb, D. J.; Bendall, L. J. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia, 2003, 17, 1294-1300. (Pubitemid 36857336)
98. Tavor, S.; Petit, I.; Porozov, S.; Avigdor, A.; Dar, A.; Leider-Trejo, L.; Shemtov, N.; Deutsch, V.; Naparstek, E.; Nagler, A.; Lapidot, T. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res., 2004, 64, 2817-2824. (Pubitemid 38500620)
99. De Falco, V.; Guarino, V.; Avilla, E.; Castellone, M. D.; Salerno, P.; Salvatore, G.; Faviana, P.; Basolo, F.; Santoro, M.; Melillo, R. M. Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res., 2007, 67, 11821-11829.
100. Barbieri, F.; Bajetto, A.; Stumm, R.; Pattarozzi, A.; Porcile, C.; Zona, G.; Dorcaratto, A.; Ravetti, J. L.; Minuto, F.; Spaziante, R.; Schettini, G.; Ferone, D.; Florio, T. Overexpression of stromal cellderived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin. Cancer Res., 2008, 14, 5022-5032.
101. Li, J. K.; Yu, L.; Shen, Y.; Zhou, L. S.; Wang, Y. C.; Zhang, J. H. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J. Gastroenterol., 2008, 14, 2308-2313. (Pubitemid 351877599)
102. Kazmierski, W. M.; Kenakin, T. P.; Gudmundsson, K. S. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. Chem. Biol. Drug Des., 2006, 67, 13-26. (Pubitemid 43881384)
103. Stone, N. D.; Dunaway, S. B.; Flexner, C.; Tierney, C.; Calandra, G. B.; Becker, S.; Cao, Y. J.; Wiggins, I. P.; Conley, J.; MacFarland, R. T.; Park, J. G.; Lalama, C.; Snyder, S.; Kallungal, B.; Klingman, K. L.; Hendrix, C. W. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob. Agents Chemother., 2007, 51, 2351-2358. (Pubitemid 47047310)
104. Hatse, S.; Princen, K.; De Clercq, E.; Rosenkilde, M. M.; Schwartz, T. W.; Hernandez-Abad, P. E.; Skerlj, R. T.; Bridger, G. J.; Schols, D. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem. Pharmacol., 2005, 70, 752-761. (Pubitemid 41058710)
105. Gudmundsson, K. S.; Sebahar, P. R.; Richardson, L. D.; Miller, J. F.; Turner, E. M.; Catalano, J. G.; Spaltenstein, A.; Lawrence, W.; Thomson, M.; Jenkinson, S. Amine substituted N-(1H-benzimidazol-2ylmethyl)-5, 6, 7, 8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1. Bioorg. Med. Chem. Lett., 2009, 19, 5048-5052.
106. Ojida, A.; Mito-oka, Y.; Sada, K.; Hamachi, I. Molecular recognition and fluorescence sensing of monophosphorylated peptides in aqueous solution by bis (zinc (II)-dipicolylamine)-based artificial receptors. J. Am. Chem. Soc., 2004, 126, 2454-2463. (Pubitemid 38295729)
107. Tamamura, H.; Ojida, A.; Ogawa, T.; Tsutsumi, H.; Masuno, H.; Nakashima, H.; Yamamoto, N.; Hamachi, I.; Fujii, N. Identification of a new class of low molecular weight antagonists against the chemokine receptor CXCR4 having the dipicolylamine-zinc (II) complex structure. J. Med. Chem., 2006, 49, 3412-3415. (Pubitemid 43830540)
108. Ichiyama, K.; Yokoyama-Kumakura, S.; Tanaka, Y.; Tanaka, R.; Hirose, K.; Bannai, K.; Edamatsu, T.; Yanaka, M.; Niitani, Y.; Miyano-Kurosaki, N.; Takaku, H.; Koyanagi, Y.; Yamamoto, N. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA, 2003, 100, 4185-4190. (Pubitemid 36418178)
109. Iwasaki, Y.; Akari, H.; Murakami, T.; Kumakura, S.; Dewan, M. Z.; Yanaka, M.; Yamamoto, N. Efficient inhibition of SDF-1alphamediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci., 2009, 100, 778-781.
110. Murakami, T.; Kumakura, S.; Yamazaki, T.; Tanaka, R.; Hamatake, M.; Okuma, K.; Huang, W.; Toma, J.; Komano, J.; Yanaka, M.; Tanaka, Y.; Yamamoto, N. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob. Agents Chemother., 2009, 53, 2940-2948.
111. Bertolini, F.; Dell'Agnola, C.; Mancuso, P.; Rabascio, C.; Burlini, A.; Monestiroli, S.; Gobbi, A.; Pruneri, G.; Martinelli, G. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res., 2002, 62, 3106-3112. (Pubitemid 34602402)
112. Gelmini, S.; Mangoni, M.; Castiglione, F.; Beltrami, C.; Pieralli, A.; Andersson, K. L.; Fambrini, M.; Taddei, G. L.; Serio, M.; Orlando, C. The CXCL12/CXCR4 axis in endometrial cancer. Clin. Exp. Metastasis, 2009, 26, 261-268.
113. Engl, T.; Relja, B.; Marian, D.; Blumenberg, C.; Muller, I.; Beecken, W. D.; Jones, J.; Ringel, E. M.; Bereiter-Hahn, J.; Jonas, D.; Blaheta, R. A. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia, 2006, 8, 290-301.
114. Lee, B. C.; Lee, T. H.; Avraham, S.; Avraham, H. K. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol. Cancer Res., 2004, 2, 327-338. (Pubitemid 39025295)
115. Baribaud, F.; Edwards, T. G.; Sharron, M.; Brelot, A.; Heveker, N.; Price, K.; Mortari, F.; Alizon, M.; Tsang, M.; Doms, R. W. Antigenically distinct conformations of CXCR4. J. Virol., 2001, 75, 8957-8967. (Pubitemid 32851900)
116. Farzan, M.; Babcock, G. J.; Vasilieva, N.; Wright, P. L.; Kiprilov, E.; Mirzabekov, T.; Choe, H. The role of post-translational modifications of the CXCR4 amino terminus in stromal-derived factor 1 alpha association and HIV-1
117. Cheng, Z.; Zhou, S.; Wang, X.; Xie, F.; Wu, H.; Liu, G.; Wang, Q.; Chen, Y.; Hu, Y.; Lu, B.; Zhang, X. Characterization and application of two novel monoclonal antibodies against human CXCR4: cell proliferation and migration regulation for glioma cell line in vitro by CXCR4/SDF-1alpha signal. Hybridoma (Larchmt), 2009, 28, 33-41.
118. Fischer, T.; Nagel, F.; Jacobs, S.; Stumm, R.; Schulz, S. Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2. PLoS One, 2008, 3, e4069.
119. Huang, C. Y.; Lee, C. Y.; Chen, M. Y.; Yang, W. H.; Chen, Y. H.; Chang, C. H.; Hsu, H. C.; Fong, Y. C.; Tang, C. H. Stromal cellderived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways. J. Cell Physiol., 2009, 221, 204-212.
120. Singh, B.; Cook, K. R.; Martin, C.; Huang, E. H.; Mosalpuria, K.; Krishnamurthy, S.; Cristofanilli, M.; Lucci, A. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin. Exp. Metastasis, 2010, 27(4), 233-40.
121. Huang, E. H.; Singh, B.; Cristofanilli, M.; Gelovani, J.; Wei, C.; Vincent, L.; Cook, K. R.; Lucci, A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J. Surg. Res., 2009, 155, 231-236.
122. Richert, M. M.; Vaidya, K. S.; Mills, C. N.; Wong, D.; Korz, W.; Hurst, D. R.; Welch, D. R. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol. Rep., 2009, 21, 761-767.
123. Porvasnik, S.; Sakamoto, N.; Kusmartsev, S.; Eruslanov, E.; Kim, W. J.; Cao, W.; Urbanek, C.; Wong, D.; Goodison, S.; Rosser, C. J. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate, 2009, 69, 1460-1469.
124. Dettin, M.; Pasquato, A.; Scarinci, C.; Zanchetta, M.; De Rossi, A.; Di Bello, C. Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1. J. Med. Chem., 2004, 47, 3058-3064. (Pubitemid 38713979)
125. Zeng, Z.; Samudio, I. J.; Munsell, M.; An, J.; Huang, Z.; Estey, E.; Andreeff, M.; Konopleva, M. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol. Cancer Ther., 2006, 5, 3113-3121. (Pubitemid 46092053)
126. Dong, C. Z.; Kumar, S.; Choi, W. T.; Madani, N.; Tian, S.; An, J.; Sodroski, J. G.; Huang, Z. Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an anti-HIV, D-amino acid-containing SMM-chemokine ligand. J. Med. Chem., 2005, 48, 7923-7924. (Pubitemid 41798424)
127. Yang, O. O.; Swanberg, S. L.; Lu, Z.; Dziejman, M.; McCoy, J.; Luster, A. D.; Walker, B. D.; Herrmann, S. H. Enhanced inhibition of human immunodeficiency virus type 1 by Met-stromal-derived factor 1beta correlates with down-modulation of CXCR4. J. Virol., 1999, 73, 4582-4589. (Pubitemid 29246716)
128. Heveker, N.; Montes, M.; Germeroth, L.; Amara, A.; Trautmann, A.; Alizon, M.; Schneider-Mergener, J. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides. Curr. Biol., 1998, 8, 369-376. (Pubitemid 28173995)
129. Crump, M. P.; Gong, J. H.; Loetscher, P.; Rajarathnam, K.; Amara, A.; Arenzana-Seisdedos, F.; Virelizier, J. L.; Baggiolini, M.; Sykes, B. D.; Clark-Lewis, I. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J., 1997, 16, 6996-7007. (Pubitemid 27520800)
130. Tudan, C.; Willick, G. E.; Chahal, S.; Arab, L.; Law, P.; Salari, H.; Merzouk, A. C-terminal cyclization of an SDF-1 small peptide analogue dramatically increases receptor affinity and activation of the CXCR4 receptor. J. Med. Chem., 2002, 45, 2024-2031. (Pubitemid 34477716)
131. Valenzuela-Fernandez, A.; Palanche, T.; Amara, A.; Magerus, A.; Altmeyer, R.; Delaunay, T.; Virelizier, J. L.; Baleux, F.; Galzi, J. L.; Arenzana-Seisdedos, F. Optimal inhibition of X4 HIV isolates by the CXC chemokine stromal cell-derived factor 1 alpha requires interaction with cell surface heparan sulfate proteoglycans. J. Biol. Chem., 2001, 276, 26550-26558.
132. Lemoli, R. M.; D'Addio, A. Hematopoietic stem cell mobilization. Haematologica, 2008, 93, 321-324. (Pubitemid 351398630)
133. Pelus, L. M.; Fukuda, S. Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. Exp. Hematol., 2006, 34, 1010-1020. (Pubitemid 44080384)
134. Villalba, S.; Salvucci, O.; Aoki, Y.; De la Luz Sierra, M.; Gupta, G.; Davis, D.; Wyvill, K.; Little, R.; Yarchoan, R.; Tosato, G. Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo. J. Leukoc. Biol., 2003, 74, 880-888. (Pubitemid 38040364)
135. Pelus, L. M.; Bian, H.; Fukuda, S.; Wong, D.; Merzouk, A.; Salari, H. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colonystimulating factor. Exp. Hematol, 2005, 33, 295-307. (Pubitemid 40261311)
136. Zhong, R.; Law, P.; Wong, D.; Merzouk, A.; Salari, H.; Ball, E. D. Small peptide analogs to stromal derived factor-1 enhance chemotactic migration of human and mouse hematopoietic cells. Exp. Hematol, 2004, 32, 470-475. (Pubitemid 38624331)
137. Perez, L. E.; Alpdogan, O.; Shieh, J. H.; Wong, D.; Merzouk, A.; Salari, H.; O'Reilly, R. J.; van den Brink, M. R.; Moore, M. A. Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice. Exp. Hematol, 2004, 32, 300-307. (Pubitemid 38328536)
138. Li, K.; Chuen, C. K.; Lee, S. M.; Law, P.; Fok, T. F.; Ng, P.C.; Li, C. K.; Wong, D.; Merzouk, A.; Salari, H.; Gu, G. J.; Yuen, P. M. Small peptide analogue of SDF-1alpha supports survival of cord blood CD34+ cells in synergy with other cytokines and enhances their ex vivo expansion and engraftment into nonobese diabetic/severe combined immunodeficient mice. Stem Cells, 2006, 24, 55-64.
139. Faber, A.; Roderburg, C.; Wein, F.; Saffrich, R.; Seckinger, A.; Horsch, K.; Diehlmann, A.; Wong, D.; Bridger, G.; Eckstein, V.; Ho, A. D.; Wagner, W. The Many Facets of SDF-1alpha, CXCR4 Agonists and Antagonists on Hematopoietic Progenitor Cells. J. Biomed. Biotechnol, 2007, 2007, 26065-26069.
140. Palladino, P.; Tizzano, B.; Pedone, C.; Ragone, R.; Rossi, F.; Saviano, G.; Tancredi, T.; Benedetti, E. Structural determinants of unexpected agonist activity in a retro-peptide analogue of the SDF-1alpha N-terminus. FEBS Lett, 2005, 579, 5293-5298. (Pubitemid 41395146)
141. Ueda, H.; Siani, M. A.; Gong, W.; Thompson, D. A.; Brown, G. G.; Wang, J. M. Chemically synthesized SDF-1alpha analogue, N33A, is a potent chemotactic agent for CXCR4/Fusin/LESTR-expressing human leukocytes. J. Biol. Chem., 1997, 272, 24966-24970. (Pubitemid 27415674)
142. Diaz, G. A. CXCR4 mutations in WHIM syndrome: a misguided immune system? Immunol. Rev., 2005, 203, 235-243. (Pubitemid 40179704)
143. Vila-Coro, A. J.; Rodríguez-Frade, J. M.; Martín de Ana, A.; Moreno-Ortíz, M. C.; Martínez-A, C.; Mellado, M. The chemokine SDF-1 a triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J., 1999, 13, 1699-1705.
144. Wang, J.; He, L.; Combs, C. A.; Roderiquez, G.; Norcross, M. A. Dimerization of CXCR4 in living malignant cells: control of cell migration by a synthetic peptide that reduces homologous CXCR4 interactions. Mol Cancer Ther., 2006, 5, 2474-2477.
145. Nijmeijer, S.; Leurs, R.; Smit, M. J.; Vischer, H. F. The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 heterooligomerizes with human CXCR4, scavenges Gai proteins, and constitutively impairs CXCR4 functioning. J Biol Chem., 2010, 285, 29632-29637.
146. Pello, O. M.; Martínez-Muñoz, L.; Parrillas, V.; Serrano, A.; Rodríguez-Frade, J. M.; Toro, M. J.; Lucas, P.; Monterrubio, M.; Martnez-A, C.; Mellado, M. Ligand stabilization of CXCR4/deltaopioid receptor heterodimers reveals a mechanism for immune response regulation. Eur. J. Immunol, 2008, 38, 537-541.
147. Sohy, D.; Parmentier, M.; Springael, J. Y. Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J. Biol. Chem., 2007, 282, 30062-30067.
148. Rodríguez-Frade, J. M.; del Real, G.; Serrano, A.; Hernanz-Falcón, P.; Soriano, S. F.; Vila-Coro, A. J.; de Ana, A. M.; Lucas, P.; Prieto, I.; Martínez-A, C.; Mellado, M. Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. EMBO J., 2004, 23, 66-70.
149. Isik, N.; Hereld, D.; Jin, T. Fluorescence resonance energy transfer imaging reveals that chemokine-binding modulates heterodimers of CXCR4 and CCR5 receptors. PLoS One, 2008, 3, e3424.
150. Contento, R. L.; Molon, B.; Boularan, C.; Pozzan, T.; Manes, S.; Marullo, S.; Viola, A. CXCR4-CCR5: a couple modulating T cell functions. Proc Natl Acad Sci USA, 2008, 105, 10101-10106.
151. Sohy, D.; Yano, H.; de Nadai, P.; Urizar, E.; Guillabert, A.; Javitch, J. A.; Parmentier, M.; Springael, J. Y. Heterooligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J. Biol Chem., 2009, 284, 31270-31278.
152. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood, 2009, 113, 6085-6089.
153. Lee, C. H.; Kakinuma, T.; Wang, J.; Zhang, H.; Palmer, D. C.; Restifo, N. P.; Hwang, S. T. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol. Cancer Ther., 2006, 5, 2592-2599. (Pubitemid 44650924)
154. Zeng, Z.; Shi, Y. X.; Samudio, I. J.; Wang, R. Y.; Ling, X.; Frolova, O.; Levis, M.; Rubin, J. B.; Negrin, R. R.; Estey, E. H.; Konoplev, S.; Andreeff, M.; Konopleva, M. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood, 2009, 113, 6215-6224.
155. Juarez, J.; Dela Pena, A.; Baraz, R.; Hewson, J.; Khoo, M.; Cisterne, A.; Fricker, S.; Fujii, N.; Bradstock, K. F.; Bendall, L. J. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia, 2007, 21, 1249-1257. (Pubitemid 46831814)
156. Poll, E. Approval given to Chemokine Therapeutics to commence Phase II trial for liver cancer. Expert Rev. Gastroenterol. Epatol., 2008, 2, 160-164.